{"id":6296,"date":"2026-02-23T10:30:49","date_gmt":"2026-02-23T09:30:49","guid":{"rendered":"https:\/\/cnatm.de\/?p=6296"},"modified":"2026-02-23T10:45:43","modified_gmt":"2026-02-23T09:45:43","slug":"rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development","status":"publish","type":"post","link":"https:\/\/cnatm.de\/en\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/","title":{"rendered":"RNATICS Secures \u20ac2.7 Million BMFTR Grant RCS-21 Advances in Clinical Development"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"6296\" class=\"elementor elementor-6296\" data-elementor-settings=\"{&quot;ha_cmc_init_switcher&quot;:&quot;no&quot;}\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6363f8b elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6363f8b\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-807a88d\" data-id=\"807a88d\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-0b60e27 elementor-widget elementor-widget-heading\" data-id=\"0b60e27\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">RNATICS Secures \u20ac2.7 Million BMFTR Grant RCS-21 Advances in Clinical Development<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-d33096d elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"d33096d\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-35ba973\" data-id=\"35ba973\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-9f642c9 elementor-widget elementor-widget-image\" data-id=\"9f642c9\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"736\" src=\"https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-1024x736.png\" class=\"attachment-large size-large wp-image-6297\" alt=\"\" srcset=\"https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-1024x736.png 1024w, https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-300x216.png 300w, https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-768x552.png 768w, https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-1536x1104.png 1536w, https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-2048x1472.png 2048w, https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-18x12.png 18w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-478b506 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"478b506\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2625714\" data-id=\"2625714\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e5c8ce5 elementor-widget elementor-widget-spacer\" data-id=\"e5c8ce5\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5c03aad elementor-widget elementor-widget-text-editor\" data-id=\"5c03aad\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>RNATICS GmbH has been awarded \u20ac2.7 million in funding from the Federal Ministry of Research, Technology and Space (BMFTR). The grant supports the next stage of clinical development for RCS-21, a first-in-class inhaled RNA therapeutic targeting severe inflammatory-fibrotic lung diseases.<\/p><p>RCS-21 uses proprietary carbohydrate conjugation for selective uptake into pulmonary macrophages, where it inhibits microRNA-21 \u2013 a key driver of pathological inflammation and fibrosis. The program focuses on patients with idiopathic pulmonary fibrosis (IPF) and related fibrotic lung conditions which currently have limited therapeutic options.<\/p><p>More at: <a href=\"https:\/\/rnatics.com\/rnatics-receives-e2-7-million-for-further-clinical-development-of-rcs-21\/\">www.rnatics.com<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-85c3739 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"85c3739\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-bcaa922\" data-id=\"bcaa922\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-d81215e elementor-blockquote--skin-boxed elementor-widget elementor-widget-blockquote\" data-id=\"d81215e\" data-element_type=\"widget\" data-widget_type=\"blockquote.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<blockquote class=\"elementor-blockquote\">\n\t\t\t<p class=\"elementor-blockquote__content\">\n\t\t\t\tThis funding marks a major milestone. It allows us to validate our macrophage-targeted platform and moves RCS-21 closer to clinical proof-of-concept for patients suffering from severe pulmonary fibrosis.\u201d \t\t\t<\/p>\n\t\t\t\t\t\t\t<div class=\"e-q-footer\">\n\t\t\t\t\t\t\t\t\t\t\t<cite class=\"elementor-blockquote__author\">Prof. Stefan Engelhardt, MD PhD, CSO &amp; Co-Founder, CNATM Speaker TUM<\/cite>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/blockquote>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-842adf5 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"842adf5\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-39a4b6c\" data-id=\"39a4b6c\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-3c2ac94 elementor-widget elementor-widget-spacer\" data-id=\"3c2ac94\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-891744f elementor-blockquote--skin-boxed elementor-widget elementor-widget-blockquote\" data-id=\"891744f\" data-element_type=\"widget\" data-widget_type=\"blockquote.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<blockquote class=\"elementor-blockquote\">\n\t\t\t<p class=\"elementor-blockquote__content\">\n\t\t\t\tThis funding will allow us to make substantial progress in the clinical development of RCS-21. Taking another step towards clinical trials is an important milestone for the translation of our research. \t\t\t<\/p>\n\t\t\t\t\t\t\t<div class=\"e-q-footer\">\n\t\t\t\t\t\t\t\t\t\t\t<cite class=\"elementor-blockquote__author\">Christina Beck, PhD project lead<\/cite>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/blockquote>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-597dc69 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"597dc69\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-d07c590\" data-id=\"d07c590\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-77a75b2 elementor-widget elementor-widget-spacer\" data-id=\"77a75b2\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Thomas Carell h\u00e4lt Vortrag beim Novo Nordisk Symposium &#8222;Frontiers in Biophysics and Chemical Biology&#8220;<\/p>","protected":false},"author":11,"featured_media":6297,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[62],"tags":[],"class_list":["post-6296","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>RNATICS Secures \u20ac2.7 Million BMFTR Grant RCS-21 Advances in Clinical Development - CNATM<\/title>\n<meta name=\"description\" content=\"RNATICS GmbH has been awarded \u20ac2.7 million in funding from the Federal Ministry of Research, Technology and Space (BMFTR). The grant supports the next stage of clinical development for RCS-21, a first-in-class inhaled RNA therapeutic targeting severe inflammatory-fibrotic lung diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cnatm.de\/en\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RNATICS Secures \u20ac2.7 Million BMFTR Grant RCS-21 Advances in Clinical Development - CNATM\" \/>\n<meta property=\"og:description\" content=\"RNATICS GmbH has been awarded \u20ac2.7 million in funding from the Federal Ministry of Research, Technology and Space (BMFTR). The grant supports the next stage of clinical development for RCS-21, a first-in-class inhaled RNA therapeutic targeting severe inflammatory-fibrotic lung diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cnatm.de\/en\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/\" \/>\n<meta property=\"og:site_name\" content=\"CNATM\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-23T09:30:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-23T09:45:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-1024x736.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"736\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Patrizia Torelli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Patrizia Torelli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/\"},\"author\":{\"name\":\"Patrizia Torelli\",\"@id\":\"https:\/\/cnatm.de\/#\/schema\/person\/f2fc8eccad93916c1b891b5fef1ac19e\"},\"headline\":\"RNATICS Secures \u20ac2.7 Million BMFTR Grant RCS-21 Advances in Clinical Development\",\"datePublished\":\"2026-02-23T09:30:49+00:00\",\"dateModified\":\"2026-02-23T09:45:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/\"},\"wordCount\":183,\"publisher\":{\"@id\":\"https:\/\/cnatm.de\/#organization\"},\"image\":{\"@id\":\"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-scaled.png\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/\",\"url\":\"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/\",\"name\":\"RNATICS Secures \u20ac2.7 Million BMFTR Grant RCS-21 Advances in Clinical Development - CNATM\",\"isPartOf\":{\"@id\":\"https:\/\/cnatm.de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-scaled.png\",\"datePublished\":\"2026-02-23T09:30:49+00:00\",\"dateModified\":\"2026-02-23T09:45:43+00:00\",\"description\":\"RNATICS GmbH has been awarded \u20ac2.7 million in funding from the Federal Ministry of Research, Technology and Space (BMFTR). The grant supports the next stage of clinical development for RCS-21, a first-in-class inhaled RNA therapeutic targeting severe inflammatory-fibrotic lung diseases.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/#primaryimage\",\"url\":\"https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-scaled.png\",\"contentUrl\":\"https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-scaled.png\",\"width\":2560,\"height\":1840},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cnatm.de\/#website\",\"url\":\"https:\/\/cnatm.de\/\",\"name\":\"CNATM\",\"description\":\"Cluster for Nucleic Acid Therapeutics Munich\",\"publisher\":{\"@id\":\"https:\/\/cnatm.de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cnatm.de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cnatm.de\/#organization\",\"name\":\"CNATM\",\"url\":\"https:\/\/cnatm.de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cnatm.de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cnatm.de\/wp-content\/uploads\/2022\/02\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg\",\"contentUrl\":\"https:\/\/cnatm.de\/wp-content\/uploads\/2022\/02\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg\",\"width\":2362,\"height\":479,\"caption\":\"CNATM\"},\"image\":{\"@id\":\"https:\/\/cnatm.de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/cnatm.de\/#\/schema\/person\/f2fc8eccad93916c1b891b5fef1ac19e\",\"name\":\"Patrizia Torelli\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cnatm.de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g\",\"caption\":\"Patrizia Torelli\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RNATICS Secures \u20ac2.7 Million BMFTR Grant RCS-21 Advances in Clinical Development - CNATM","description":"RNATICS GmbH has been awarded \u20ac2.7 million in funding from the Federal Ministry of Research, Technology and Space (BMFTR). The grant supports the next stage of clinical development for RCS-21, a first-in-class inhaled RNA therapeutic targeting severe inflammatory-fibrotic lung diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cnatm.de\/en\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/","og_locale":"en_US","og_type":"article","og_title":"RNATICS Secures \u20ac2.7 Million BMFTR Grant RCS-21 Advances in Clinical Development - CNATM","og_description":"RNATICS GmbH has been awarded \u20ac2.7 million in funding from the Federal Ministry of Research, Technology and Space (BMFTR). The grant supports the next stage of clinical development for RCS-21, a first-in-class inhaled RNA therapeutic targeting severe inflammatory-fibrotic lung diseases.","og_url":"https:\/\/cnatm.de\/en\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/","og_site_name":"CNATM","article_published_time":"2026-02-23T09:30:49+00:00","article_modified_time":"2026-02-23T09:45:43+00:00","og_image":[{"width":1024,"height":736,"url":"https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-1024x736.png","type":"image\/png"}],"author":"Patrizia Torelli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Patrizia Torelli","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/#article","isPartOf":{"@id":"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/"},"author":{"name":"Patrizia Torelli","@id":"https:\/\/cnatm.de\/#\/schema\/person\/f2fc8eccad93916c1b891b5fef1ac19e"},"headline":"RNATICS Secures \u20ac2.7 Million BMFTR Grant RCS-21 Advances in Clinical Development","datePublished":"2026-02-23T09:30:49+00:00","dateModified":"2026-02-23T09:45:43+00:00","mainEntityOfPage":{"@id":"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/"},"wordCount":183,"publisher":{"@id":"https:\/\/cnatm.de\/#organization"},"image":{"@id":"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/#primaryimage"},"thumbnailUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-scaled.png","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/","url":"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/","name":"RNATICS Secures \u20ac2.7 Million BMFTR Grant RCS-21 Advances in Clinical Development - CNATM","isPartOf":{"@id":"https:\/\/cnatm.de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/#primaryimage"},"image":{"@id":"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/#primaryimage"},"thumbnailUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-scaled.png","datePublished":"2026-02-23T09:30:49+00:00","dateModified":"2026-02-23T09:45:43+00:00","description":"RNATICS GmbH has been awarded \u20ac2.7 million in funding from the Federal Ministry of Research, Technology and Space (BMFTR). The grant supports the next stage of clinical development for RCS-21, a first-in-class inhaled RNA therapeutic targeting severe inflammatory-fibrotic lung diseases.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cnatm.de\/rnatics-secures-e2-7-million-bmftr-grant-rcs-21-advances-in-clinical-development\/#primaryimage","url":"https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-scaled.png","contentUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2026\/02\/20260212_Foto_RNATICS_PM-scaled.png","width":2560,"height":1840},{"@type":"WebSite","@id":"https:\/\/cnatm.de\/#website","url":"https:\/\/cnatm.de\/","name":"CNATM","description":"Cluster for Nucleic Acid Therapeutics Munich","publisher":{"@id":"https:\/\/cnatm.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cnatm.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cnatm.de\/#organization","name":"CNATM","url":"https:\/\/cnatm.de\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cnatm.de\/#\/schema\/logo\/image\/","url":"https:\/\/cnatm.de\/wp-content\/uploads\/2022\/02\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg","contentUrl":"https:\/\/cnatm.de\/wp-content\/uploads\/2022\/02\/CNATM-Logo-mit-Zusatz-RGB-bunt-schwarz.jpg","width":2362,"height":479,"caption":"CNATM"},"image":{"@id":"https:\/\/cnatm.de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/cnatm.de\/#\/schema\/person\/f2fc8eccad93916c1b891b5fef1ac19e","name":"Patrizia Torelli","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cnatm.de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/87ab0132dfbaaa804847124811e093cdf95fa3b96905aba129559c779a1ff8eb?s=96&d=mm&r=g","caption":"Patrizia Torelli"}}]}},"_links":{"self":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts\/6296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/comments?post=6296"}],"version-history":[{"count":5,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts\/6296\/revisions"}],"predecessor-version":[{"id":6302,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/posts\/6296\/revisions\/6302"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/media\/6297"}],"wp:attachment":[{"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/media?parent=6296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/categories?post=6296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cnatm.de\/en\/wp-json\/wp\/v2\/tags?post=6296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}